Filing Flows › Northwest Biotherapeutics (NWBO) › Q2 2026 › vs Q1 2026
Northwest Biotherapeutics (NWBO) Q2 2026 vs Q1 2026 (quarter over quarter)
Northwest Biotherapeutics's revenue rose $313K (+63%) from $494K in Q1 2026 to $807K in Q2 2026.
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $807K | $494K | $313K | +63% |
| Net loss | $15.4M | −$3.1M | $18.5M | — |
| Costs & expenses | $16.2M | $14.5M | $1.7M | +12% |
| Operating costs | $12.4M | $11.4M | $1.0M | +9% |
| Interest & other, net | $3.8M | −$14.0M | $17.8M | — |
| Research & development | $5.7M | $4.9M | $847K | +17% |
| General & admin | $6.7M | $6.5M | $171K | +3% |
| Operating cash sources | $15.4M | −$3.1M | $18.5M | — |
| Depreciation & amortization | $774K | $771K | $3K | +0.4% |
| Share-based compensation | $181K | $288K | −$107K | -37% |
| Working capital & other | $7.3M | −$16.7M | $23.9M | — |
| Cash used in operations | $7.2M | $12.5M | −$5.3M | -43% |
| Net loss absorbed | $15.4M | −$3.1M | $18.5M | — |
Questions
How much did Northwest Biotherapeutics's revenue grow quarter over quarter in Q2 2026?
Northwest Biotherapeutics's revenue rose $313K (+63%) from $494K in Q1 2026 to $807K in Q2 2026.